Brind.
  1. Glenmark Pharmaceuticals is seeking marketing authorization for its products in key European markets.

Glenmark launched an equivalent drug to Merck's BRIDION.

2 reports, 1 independent Updated Jul 30
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Glenmark launched an equivalent drug to Merck's BRIDION.

Who's involved

What this event is mainly about
Glenmark Pharmaceuticals

Keep exploring

Part of

Glenmark Pharmaceuticals is seeking marketing authorization for its products in key European markets. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • prnewswire.comGlenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
1 more outlet ran the same wire story